

**G** \*click [HERE](#) for an explanation of standardised wording to be used by Scottish Boards regarding decisions on medicines since May 2016 [Link to Formulary](#)

Medicine	Indication	NHS Board Decision*	DTC Supplement	Date
Galcanezumab 120mg solution for injection in pre-filled pen (Emgality®) SMC2313	Indication under review: prophylaxis of migraine in adults who have at least 4 migraine days per month. SMC restriction: for the treatment of patients with chronic and episodic migraine who have had prior failure on three or more migraine preventive treatments. In studies in patients with episodic and chronic migraine, galcanezumab significantly reduced the number of migraine days per month compared with placebo.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">184</a>	May 2021
Galantamine (Reminyl XL®)	Alzheimer's dementia	GPs may prescribe under the direction of a dementia specialist	<a href="#">52</a>	2005
Gefitinib (Iressa) (615/10)	Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of epidermal growth factor receptor tyrosine kinase (EGFR-TK). SMC Restriction: in patients with previously untreated locally advanced or metastatic NSCLC with activating EGFR-TK mutations i.e. as a first-line therapy.	Non-Formulary Pending local decision	<a href="#">101</a> <a href="#">96</a> <a href="#">153</a>	Dec 10/Jan 2011 Apr/May 2010 Jan/Feb 2016
Gemcitabine (Gemzar®)	Metastatic breast cancer	HOSPITAL ONLY	<a href="#">64</a> <a href="#">49</a>	2006 2005
Gemtuzumab ozogamicin 5mg powder for concentrate for solution for infusion (Mylotarg®) SMC No2089	For combination therapy with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or	<a href="#">172</a>	Dec 2018

	<p>(APL).</p> <p>SMC restriction: use in patients with a favourable, intermediate or unknown cytogenetic profile.</p> <p>In an open label, phase III study of adults with AML, the addition of gemtuzumab ozogamicin to standard intensive chemotherapy was associated with significant improvement in event free survival compared with standard intensive chemotherapy alone. Events included failure to achieve remission with induction therapy, relapse of disease, or death.</p>	there is a local preference for alternative medicines		
Gilteritinib 40mg film-coated tablets (Xospata®) SMC2252	<p>As monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia with a FLT3 mutation.</p> <p>In an open-label, phase III study, gilteritinib improved overall survival compared with salvage chemotherapy in patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation</p>	Available in line with national guidance	<a href="#">181</a>	November 2020
givosiran 189mg/mL solution for injection (Givlaari®) SMC2470	Treatment of acute hepatic porphyria in adults and adolescents aged 12 years and older.	Not available as not recommended for use in NHS Scotland	<a href="#">188</a>	April 2022
Glatiramir acetate 40mg/mL solution for injection prefilled syringes (Copaxone®) SMC No. 1108/15	Treatment of relapsing forms of multiple sclerosis (MS).	Available in line with local guidance for prescribing	<a href="#">153</a>	Jan/Feb 2016
Glecaprevir/pibrentasvir 100mg/40mg film-coated tablets (Maviret®) SMC2214	Treatment of chronic hepatitis C virus (HCV) infection in adolescents aged 12 to <18 years.	Available in line with national guidance	<a href="#">178</a>	Feb 2020
Glecaprevir 100mg, pibrentasvir 40mg film-coated tablet	Treatment of chronic hepatitis C virus (HCV) infection in adults	Available in line with National guidance	<a href="#">165</a>	Jan 2018

(Maviret®) SMC No 1278/17				
Glibenclamide 0.6mg/mL, 6mg/ml oral suspension (Amglidia®) SMC2237	Treatment of neonatal diabetes mellitus, for use in newborns, infants and children.		<a href="#">177</a>	Dec 2019
Glucosamine sulphate (Glusartel®) (647/10)	Mild to moderate osteoarthritis (OA) of the knee.	Not recommended	<a href="#">109</a> <a href="#">100</a>	Sept 2011 Oct/Nov 2010
Glucosamine sulphate (Dolenio®) (729/11)	Mild to moderate osteoarthritis (OA) of the knee.	Not recommended	<a href="#">109</a>	Sept 2011
Glucosamine hydrochloride (Alateris®) (471/08)	Mild to moderate osteoarthritis of the knee	Not recommended	<a href="#">80</a>	June 2008
Glycerol phenylbutyrate 1.1g/mL oral liquid (Ravicti®) SMC No 1342/18	<p>For use as adjunctive therapy for chronic management of adult and paediatric patients <math>\geq 2</math> months of age with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate synthase I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. Glycerol phenylbutyrate must be used with dietary protein restriction and, in some cases, dietary supplements (e.g. essential amino acids, arginine, citrulline, protein-free calorie supplements).</p> <p>Glycerol phenylbutyrate is non-inferior to sodium phenylbutyrate for control of blood ammonia levels in patients with UCDs.</p>	Available in line with national guidance	<a href="#">170</a>	Sep 2018
Glyceryl trinitrate 0.4% rectal ointment (Rectogesic®) (200/05)	Chronic anal fissure	Not recommended	<a href="#">77</a> <a href="#">67</a> <a href="#">57</a>	Mar 2008 Mar 2007 2006

			<a href="#">54</a>	2005
Glycopyrronium 320 micrograms/mL (glycopyrronium bromide 400 micrograms/mL) oral solution (Sialanar®) SMC No. (1254/17)	Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders. The availability of glycopyrronium (Sialanar®) provides a licensed alternative to an existing generic preparation used outwith the terms of its marketing authorisation, at a small additional cost.	Available in line with national guidance	<a href="#">163</a>	Sep 2017
Glycopyrronium (Seebri Breezhaler®) (829/12)	Maintenance treatment of COPD	Formulary	<a href="#">124</a>	Feb 2013
Glycopyrronium/formoterol fumarate pressurised inhalation suspension (Bevespi) SMC 2652	As a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).		197	May 2024
Golimumab 50mg solution for injection in pre-filled pen / 50mg solution for injection in pre-filled syringe (Simponi®) SMC2203	In combination with methotrexate for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older who have responded inadequately to previous therapy with methotrexate.	Not available as not recommended for use in NHS Scotland.	<a href="#">175</a>	Aug 2019
Golimumab 50mg solution for injection (Simponi®) SMC 1199/16	In combination with methotrexate for the treatment of polyarticular juvenile idiopathic arthritis in children with a body weight of at least 40 kg, who have responded inadequately to previous therapy with methotrexate.	Not available as not recommended for use in NHS Scotland.	<a href="#">158</a>	Dec 2016
Golimumab (Simponi®) (946/13)	Treatment of moderately to severely active ulcerative colitis in adult patients	HOSPITAL ONLY Gastroenterology List	<a href="#">141</a>  <a href="#">134</a> <a href="#">149</a>	Sept/Oct 2014 Jan/Feb 2014 Jun/Jul 2015
Golimumab (Simponi®) (674/11)	Active and progressive psoriatic arthritis	HOSPITAL ONLY (Rheumatology Clinic)	<a href="#">119</a>	Aug/Sept 2012

Golimumab (Simponi®) (733/11)	Active rheumatoid arthritis and severe, active ankylosing spondylitis in adults	HOSPITAL ONLY (Rheumatology Clinic)	<a href="#">112</a>	Dec 2011
Golimumab (Simponi®) (721/11)	Active and progressive psoriatic arthritis	HOSPITAL ONLY (Rheumatology Clinic)	<a href="#">110</a> <a href="#">103</a>	Oct 2011 Feb/Mar 2011
Golimumab 50mg/0.5mL solution for injection in pre-filled pen or syringe and 100mg/mL solution for injection in pre-filled pen (Simponi®) (1124/16)	Treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation	Available in line with local guidance for prescribing.	<a href="#">154</a> <a href="#">155</a>	May 2016 June 2016
Granisetron (Sancuso®) (895/13)	Prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy.	HOSPITAL ONLY	<a href="#">131</a>	Oct/Nov 2013
Grazax® (standardised allergen extract of grass pollen) (367/07)	Grass pollen induced rhinitis and conjunctivitis in adults	Not recommended	<a href="#">76</a> <a href="#">68</a>	Jan 2008 May 2007
Guanfacine, 1mg, 2mg, 3mg and 4mg prolonged-release tablets (Intuniv®) SMC 1123/16	Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.	Available in line with local guidance for prescribing.	<a href="#">154</a> <a href="#">157</a>	May 2016 Nov 2016
Guselkumab 100mg solution for injection in pre-filled pen or syringe (Tremfya®) SMC2360	Alone or in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy. SMC restriction: (i) patients whose disease has not responded adequately or who have been intolerant to two previous conventional disease-modifying antirheumatic drug (DMARD) therapies but have not received biologic DMARD therapy	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">186</a>	Sept 2021

	(biologic-naïve population); (ii) patients whose disease has not responded adequately to conventional dmards and one or more tumour necrosis factor (TNF) inhibitors (biologic-experienced population); and (iii) patients in whom TNF inhibitors are contraindicated or not tolerated.			
Guselkumab 100mg solution for injection (Tremfya®) SMC No 1340/18	<p>Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.</p> <p>SMC restriction: for patients who have failed to respond to conventional systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contraindication to these treatments.</p>	Available in line with national guidance	<a href="#">169</a>	July 2018

Updated: 15<sup>th</sup> March 2024

[Back to top](#)

[Back to homepage](#)